1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study
(
- Contribution to journal › Article
- 2013
-
Mark
Contribution of IKBKE and IFIH1 gene variants to SLE susceptibility
(
- Contribution to journal › Article
- 2011
-
Mark
Systemic lupus erythematosus and cardiac risk factors: medical record documentation and patient adherence
(
- Contribution to journal › Article
- 2010
-
Mark
Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006
(
- Contribution to journal › Article
- 2009
-
Mark
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas:relative risks and time-trends in the Swedish Biologics Register
(
- Contribution to journal › Article
- 2005
-
Mark
The R620W C/T polymorphism of the gene PTPN22 is associated with SLE independently of the association of PDCD1
(
- Contribution to journal › Article
-
Mark
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article